IMDX vs SRTA
IMDX: iMDx develops decentralized molecular diagnostic kits for transplant organ rejection monitoring using donor-derived cell-free DNA biomarkers, enabling in-house testing at hospitals rather than centralized lab services. SRTA: A time-critical logistics and clinical services provider offering integrated air/ground organ transport, surgical organ recovery, and cardiac perfusion solutions to the U.S. transplant ecosystem.
Side-by-side fundamentals
| Metric | IMDX | SRTA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $4.70 | $5.14 | |
| Market cap as of 2026-08-02 | $150M | $445M | |
| P/E as of 2026-08-02 | n/a | 9.24 | |
| Net margin as of 2026-08-02 | -2454.6% | +18.5% | SRTA higher |
| Gross margin as of 2026-08-02 | +51.3% | -39.7% | IMDX higher |
| Operating margin as of 2026-08-02 | -2500.7% | -7.8% | SRTA higher |
| ROE as of 2026-08-02 | -426.7% | +17.5% | SRTA higher |
| ROA as of 2026-08-02 | -119.1% | +15.1% | SRTA higher |
| Debt / equity as of 2026-08-02 | 0.92 | 0.00 | SRTA lower |
| Revenue growth (YoY) as of 2026-08-02 | -49.3% | +19.6% | SRTA higher |
| Revenue CAGR (3y) SEC XBRL | +61.8% | +10.5% | IMDX higher |
| Beta as of 2026-08-02 | 1.84 | 2.27 | |
| 1-year return as of 2026-07-27 close | +62.9% | +19.5% | IMDX higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.